Distribution of Substance P Receptors on Murine Spleen and Peyer's Patch T and B Cells
Overview
Affiliations
Previous studies have demonstrated that the sensory neuropeptide substance P (SP) can modulate immune responses in vitro. Work from this laboratory has shown that SP enhances immunoglobulin synthesis by murine splenic and Peyer's patch lymphocytes stimulated with concanavalin A. One mechanism underlying these effects is the binding of SP to specific receptors on lymphocytes. We examined the distribution of SP receptors on murine T and B lymphocytes and their subsets by one and two color fluorescence-activated cell sorter analysis. The specificity and nature of binding was examined using radiolabeled SP, and competitive inhibition experiments were performed with cold SP. In cytofluorimetry experiments, both T and B lymphocytes from Peyer's patches and spleen were bound to SP, with those from Peyer's patches having a higher proportion than lymphocytes from the spleen. The majority of T cells from both organs bound SP with binding being evenly distributed between Lyt-1+ and Lyt-2+ cells. Similarly, the majority of B lymphocytes from spleen and Peyer's patches showed SP binding. There were no significant isotype-specific differences within any organ. Studies using 125I-labeled SP showed specific binding to all lymphocyte subpopulations examined. SP receptors were fewer in number on cells isolated from spleen than on cells from Peyer's patches although the dissociation constants were similar for all populations examined. These studies demonstrated that SP receptors are present both on murine T and B lymphocytes from Peyer's patches and spleen. There is no evidence for differential SP receptor expression on distinct lymphocyte subsets in spleen or Peyer's patches.
Regulation of Carcinogenesis by Sensory Neurons and Neuromediators.
Erin N, Shurin G, Baraldi J, Shurin M Cancers (Basel). 2022; 14(9).
PMID: 35565462 PMC: 9102554. DOI: 10.3390/cancers14092333.
Neurokinin receptors and their implications in various autoimmune diseases.
Mishra A, Lal G Curr Res Immunol. 2022; 2:66-78.
PMID: 35492389 PMC: 9040085. DOI: 10.1016/j.crimmu.2021.06.001.
Neuroimmunomodulation in the Gut: Focus on Inflammatory Bowel Disease.
Bernardazzi C, Pego B, de Souza H Mediators Inflamm. 2016; 2016:1363818.
PMID: 27471349 PMC: 4947661. DOI: 10.1155/2016/1363818.
Amadesi S, Reni C, Katare R, Meloni M, Oikawa A, Beltrami A Circulation. 2012; 125(14):1774-86, S1-19.
PMID: 22392530 PMC: 3616366. DOI: 10.1161/CIRCULATIONAHA.111.089763.
Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor.
Khan M, Douglas S, Benton T J Neuroimmunol. 2011; 242(1-2):1-8.
PMID: 22115773 PMC: 3278501. DOI: 10.1016/j.jneuroim.2011.10.012.